Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × Albumin-Bound Paclitaxel × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 138 Breast Neoplasms 108 Carcinoma, Non-Small-Cell Lung 61 Neoplasm Metastasis 40 Triple Negative Breast Neoplasms 37 Neoplasms 36 Lung Neoplasms 23 Ovarian Neoplasms 22 Squamous Cell Carcinoma of Head and Neck 21 Stomach Neoplasms 19 Esophageal Neoplasms 16 Melanoma 15 Adenocarcinoma 13 Recurrence 10 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Head and Neck Neoplasms 10 Fallopian Tube Neoplasms 10 Cholangiocarcinoma 10 Esophageal Squamous Cell Carcinoma 9 Urinary Bladder Neoplasms 8 Sarcoma 8 Uterine Cervical Neoplasms 7 Small Cell Lung Carcinoma 7 Pancreatic Adenocarcinoma 7 Colorectal Neoplasms 7 Carcinoma, Pancreatic Ductal 7 Breast Neoplasms, Male 7 Prostatic Neoplasms 6 Inflammatory Breast Neoplasms 6 Carcinoma 6

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡